scholarly journals Impact of Total Body Irradiation on Successful Neutrophil Engraftment in Unrelated Bone Marrow or Cord Blood Transplantation

Blood ◽  
2016 ◽  
Vol 128 (22) ◽  
pp. 3423-3423
Author(s):  
Hideki Nakasone ◽  
Kimikazu Yakushijin ◽  
Shigeo Fuji ◽  
Makoto Onizuka ◽  
Akihito Shinohara ◽  
...  

Abstract [Background] Total body irradiation (TBI) has been thought to help donor cell engraftment in allogeneic hematopoietic cell transplantation (HCT) from alternative donors by killing recipientfs T cells. On the other hand, it might increase non-relapse adverse events due to induction or deterioration of inflammatory states following conditioning, leading in organ damages. However, the clinical significance of TBI may be changed by recent progress of HCT strategies, including donor selection algorithms, conditioning intensity, prophylaxis of graft-versus-host disease (GVHD), practical antibiotics usage during febrile neutropenia, and various supportive cares. Thus, the impact of TBI on neutrophil engraftment following HCT was retrospectively analyzed, using Japanese transplant registry database. [Patients and methods] We retrospectively analyzed 3933 adult recipients (>15 y.o.) who underwent HCT between 2006 and 2013 from 8/8 HLA-matched unrelated bone marrow donor (MUD, n=1367), HLA-mismatched unrelated bone marrow donor (MMUD, n=1102), and unrelated cord blood (UCB, n=1464). HCT using unrelated peripheral blood stem cells was excluded because it was currently too small in Japan. Only standard-risk leukemia patients were included: 1st or 2nd complete remission of acute myelogenous leukemia or acute lymphoblastic leukemia, 1st or 2nd chronic phase of chronic myeloid leukemia, and myelodysplastic syndrome other than refractory anemia with excess blasts. Conditioning regimens were divided into 5 groups: High-TBI (>=12Gy) myeloablative conditioning (MAC), fludarabine (Flu)-based Low-TBI (<=8Gy) MAC, no-TBI MAC, Flu-based Low-TBI (<=8Gy) reduced-intensity conditioning (RIC), and Flu-based no-TBI RIC. First, the impact of TBI on cumulative neutrophil engraftment was individually analyzed in overall MUD, MMUD, and UCB cohorts. Next, we evaluated the effects of TBI in UCB subgroups stratified according to conditioning intensity, number of HLA-mismatch, and the presence of anti-HLA antibodies. [Results] Neutrophil engraftment was sufficiently achieved among the High-TBI-MAC, Low-TBI-MAC, no-TBI-MAC, Low-TBI-RIC, and no-TBI-RIC groups both in MUD (>95% in all regimens at day 30) and MMUD (>92% in all regimens at day30) (Figure 1), and TBI was not significantly associated with prompt neutrophil engraftment in multivariate analyses. On the other hand, in UCB, no-TBI-MAC and -RIC groups had lower neutrophil engraftment compared with TBI-regimens (86% in High-TBI-MAC vs. 87% in Low-TBI-MAC vs. 70% in no-TBI-MAC vs. 85% in Low-TBI-RIC vs. 76% in no-TBI-RIC at day-60, P<0.001, Figure1). In multivariate analyses, TBI-regimens in UCB were significantly associated with successful neutrophil engraftment (HR 1.41, P=0.021 in High-TBI-MAC; HR 1.90 in Low-TBI-MAC, P<0.001; HR 1.57 in Low-TBI-RIC, P<0.01), after adjusting for age, gender, performance status, disease type, GVHD prophylaxis, use of in vivo T-cell depletion, infused cell doses, and use of granulocyte-colony stimulating factor. This beneficial effect on engraftment from TBI-based regimens was also observed in the UCB subgroups stratified according to conditioning intensity. Therefore, we subsequently focused only on HCT from UCB, and assessed the beneficial effect of TBI on neutrophil engraftment in the subgroups stratified according to number of HLA allele match, and the presence of anti-HLA antibodies. In the subgroups by number of HLA allele match, TBI-regimens were significantly associated with successful neutrophil engraftment only in recipients who received UCB with 4/6 or less HLA allele match, while the beneficial effect by TBI was not observed in those with 6/6 or 5/6 HLA allele match (Figure 2). Additionally, focusing on recipients who had anti-HLA antibodies (n=173, Figure 3), TBI-based regimens were significantly associated with successful neutrophil engraftment (HR 2.38 in High-TBI regimens, P=0.017; HR 2.23 in Low-TBI regimens, P=0.016). [Conclusion] TBI-regimens had neither impact on neutrophil engraftment in the current practice of unrelated bone marrow transplantation. However, in UCB transplantation, TBI is still necessary to enhance engraftment, no matter what conditioning intensity is selected. Especially, recipients from UCB with two or more allele mismatches or with anti-HLA antibodies may benefit from adding TBI into conditioning. Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2012 ◽  
Vol 120 (13) ◽  
pp. 2600-2609 ◽  
Author(s):  
Maegan L. Capitano ◽  
Michael J. Nemeth ◽  
Thomas A. Mace ◽  
Christi Salisbury-Ruf ◽  
Brahm H. Segal ◽  
...  

Abstract Neutropenia is a common side effect of cytotoxic chemotherapy and radiation, increasing the risk of infection in these patients. Here we examined the impact of body temperature on neutrophil recovery in the blood and bone marrow after total body irradiation (TBI). Mice were exposed to either 3 or 6 Gy TBI followed by a mild heat treatment that temporarily raised core body temperature to approximately 39.5°C. Neutrophil recovery was then compared with control mice that received either TBI alone heat treatment alone. Mice that received both TBI and heat treatment exhibited a significant increase in the rate of neutrophil recovery in the blood and an increase in the number of marrow hematopoietic stem cells and neutrophil progenitors compared with that seen in mice that received either TBI or heat alone. The combination treatment also increased G-CSF concentrations in the serum, bone marrow, and intestinal tissue and IL-17, IL-1β, and IL-1α concentrations in the intestinal tissue after TBI. Neutralizing G-CSF or inhibiting IL-17 or IL-1 signaling significantly blocked the thermally mediated increase in neutrophil numbers. These findings suggest that a physiologically relevant increase in body temperature can accelerate recovery from neutropenia after TBI through a G-CSF–, IL-17–, and IL-1–dependent mechanism.


Blood ◽  
2007 ◽  
Vol 110 (11) ◽  
pp. 5071-5071
Author(s):  
Margaret L. MacMillan ◽  
Bruce R. Blazar ◽  
Todd E. DeFor ◽  
Kathryn R. Dusenbery ◽  
Jakub Tolar ◽  
...  

Abstract Major advances have been made that have improved survival in FA patients undergoing alternate donor hematopoietic stem cell transplantation (AD-HSCT). While addition of fludarabine (FLU) to cyclophosphamide (CY) and single dose total body irradiation (450 cGy TBI) has been the single most important factor improving engraftment rates in FA patients, risks of infection and late effects remain important challenges. Seeking to reduce these risks, we hypothesized that FA patients undergoing AD-HSCT could reliably achieve neutrophil engraftment with less or no irradiation due to the profound immunosuppressive effects of FLU. Therefore, we conducted a single center, single arm, TBI dose de-escalation trial designed to determine the lowest possible dose of TBI required for engraftment in recipients of T cell depleted bone marrow (TCD BM) or umbilical cord blood (UCB) from AD. All patients received CY 10 mg/kg x 4 days, FLU 35 mg/m2 x 4 days, ATG 30 mg/kg x 5 days and a single fraction of TBI with CT guided thymic shielding. TBI dose de-escalation strata were: TBI 300 cGy (cohort 1); TBI 150 cGy (cohort 2); no TBI (cohort 3). All patients received CSA and methylprednisolone as GVHD prophylaxis and G-CSF 5 ug/kg/day until engraftment. The decision to proceed with each stepwise decrease in TBI is based upon achieving primary neutrophil engraftment in 10 of 10 patients at each dose level or 14 of 15 patients if one graft failure is observed in the first 10 patients. More than 1 graft failure in 15 patients was considered unacceptable and the next higher TBI dose level was thereafter to be considered the optimal dose. Between July 2006-July 2007, 13 FA patients were enrolled with 11 in cohort I (as patient 11 was enrolled prior to proven engraftment in patient 10) and 2 thus far in cohort 2. All patients achieved primary engraftment at a median of 11 days after HSCT. One patient (TBI 300) however developed secondary graft failure at day 178 and died at day 253. Two patients developed grade II acute GVHD and none developed chronic GVHD. With a median follow up of 10.2 months, 12 of 13 patients are alive with complete chimerism and no active GVHD. Patient Characteristics and HSCT Outcomes UPN TBI Dose Age, Sex Donor Day to ANC>500 Acute GVHD Complications Survival (days) 4413 300 17.3, M 8/8 URD BM 10 - Aspergillus, secondary GF, MSOF died day 253 4417 300 9.5, M 7/8 URD BM 16 grade 2 PRESS 403+ 4425 300 8.0, M 8/8 URD BM 11 - PRESS, hem cystitis, pneumonia 392+ 4438 300 19.4, F 8/8 URD BM 11 - - 374+ 4456 300 9.1, M 8/8 URD BM 10 - Aspergillus pneumonia 354+ 4465 300 12.1, M 5/6 URD UCB 11 grade 2 Pulmonary cytolytic thrombi 335+ 4480 300 8.1, M 7/8 URD BM 10 - Hem cystitis 312+ 4538 300 12.9, F 5/6 URD UCB 30 - - 207+ 4601 300 11.2, M 8/8 URD BM 10 - - 124+ 4650 300 5.2, F 8/8 URD BM 9 - - 45+ 4655 300 6.1, F 7/8 RD BM 12 - Bacteremia 34+ 4660 150 7.3, F 8/8 URD BM 10 - Bacteremia 27+ 4662 150 22.3, M 8/8 URD BM 12 - - 24+ The results demonstrate that TBI 450 cGy is not required for engraftment in recipients of CY-FLU-ATG and HLA matched or mismatched TCD BM or UCB from AD. While longer followup is needed to quantitate the impact of lower dose radiation on risks of infection and therapy-related late effects, TBI 450 cGy should no longer be considered the standard of care.


2017 ◽  
Vol 92 (2) ◽  
pp. e24613 ◽  
Author(s):  
Hideki Nakasone ◽  
Fuji Shigeo ◽  
Kimikazu Yakushijin ◽  
Makoto Onizuka ◽  
Akihito Shinohara ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document